Pooled analysis of the prognostic and predictive effects of KRAS mutation status and KRAS mutation subtype in early-stage resected non-small-cell lung cancer in four trials of adjuvant chemotherapy.
Shepherd FA, Domerg C, Hainaut P, Jänne PA, Pignon JP, Graziano S, Douillard JY, Brambilla E, Le Chevalier T, Seymour L, Bourredjem A, Le Teuff G, Pirker R, Filipits M, Rosell R, Kratzke R, Bandarchi B, Ma X, Capelletti M, Soria JC, Tsao MS.
Shepherd FA, et al. Among authors: ma x.
J Clin Oncol. 2013 Jun 10;31(17):2173-81. doi: 10.1200/JCO.2012.48.1390. Epub 2013 Apr 29.
J Clin Oncol. 2013.
PMID: 23630215
Free PMC article.
Clinical Trial.